Lipoprotein(a) Reporting by Australian Chemical Pathology Laboratories

Heart Lung Circ. 2026 Oct 15:S1443-9506(26)00425-7. doi: 10.1016/j.hlc.2026.05.016. Online ahead of print.ABSTRACTBACKGROUND: Levels of lipoprotein(a) [Lp(a)] are largely genetically determined and represent a causal risk factor for atherosclerotic cardiovascular disease. International recommendatio

J Jeff R Ma

Accelerated Systemic Atherosclerosis Following Immune-Related Adverse Events in a Patient with Primary Thoracic Melanoma: A Case of Sequential Coronary and Peripheral Revascularization

Intern Med. 2026 Oct 15. doi: 10.2169/internalmedicine.8340-26. Online ahead of print.ABSTRACTImmune checkpoint inhibitors (ICIs) improve survival in advanced melanoma, but they may accelerate atherosclerosis, particularly in patients with immune-related adverse events (irAEs). A 64-year-old man wit

T Tomoaki Nishikawa

Role of 12/15-lipoxygenase and its metabolites in cardiovascular diseases

J Lipid Res. 2026 Oct 14:101172. doi: 10.1016/j.jlr.2026.101172. Online ahead of print.ABSTRACT12/15-Lipoxygenase (12/15-LOX), a key oxidoreductase enzyme, catalyzes the peroxidation of polyunsaturated fatty acids (PUFAs) including omega-6 and omega-3 fatty acids. This enzyme is expressed in multipl

J Jiaqi Yu